Microbial test guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA 1draft guidance released Dec. 8 advises on important technical premarket review issues for genetic assays designed to detect the presence or absence of microbial pathogens. The document, which includes sections on appropriate labeling as well as on assessing analytical and clinical performance of such products, is meant as a general guideline for nucleic acid microbial assays, which can either require 510(k) clearance or PMA approval...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.